Recorded in-person in Minneapolis, this conversation reflects the kind of cross-regional connections shaping the Midwest’s medtech and biotech ecosystem.

In this episode of Favorable Environments, Tung Nguyen speaks with Ian Weimer, Founder of Weimer Analytics, about bringing real world evidence and advanced health economics analytics to small and medium-sized medtech and biotech companies.

Ian brings experience from a boutique healthcare consultancy where he contributed to 16 peer-reviewed publications and regulatory submissions for Fortune 500 pharma and medical device firms—to launching his own firm in 2025 to fill a clear gap: making sophisticated, tailored evidence generation accessible beyond large incumbents.

The conversation explores how real world evidence (RWE) is helping early-stage innovators quantify disease burden, demonstrate product value before launch, and attract investment in a challenging funding environment.

Ian also breaks down the FDA’s December 2025 guidance update, which is far more accepting of de-identified real world data for initial approvals—a shift he expects to accelerate adoption across early-stage companies. He also discusses how AI is acting as a multiplier for smaller firms, turning months-long analyses into work that can now be completed in hours or days.

This episode offers a grounded look at how real-world evidence and data science are leveling the playing field for the next generation of healthcare innovators—and why the Midwest continues to create favorable environments for evidence-based entrepreneurship and commercialization.